Blar i NTNU Open på forfatter "Gimsing, Peter"

Viser treff 1-4 av 4

    • Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study 

      Nielsen, Lene Kongsgaard; Stege, Claudia; Lissenberg-Witte, Birgit I.; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus; van der Velden, Annette W.G.; Deenik, Wendy; Coenen, Juleon; Hinge, Maja; Klein, Saskia K.; Tanis, Bea C.; Szatkowski, Damian Lukasz; Brouwer, Rolf E.; Westerman, Matthijs; Leys, Rineke; Sinnige, Harm A.M.; Haukås, Einar; van der Hem, Klaas G.; Durian, Marc F.; Gimsing, Peter; van de Donk, Niels; Sonneveld, Pieter; Waage, Anders; Abildgaard, Niels; Zweegman, Sonja (Peer reviewed; Journal article, 2019)
      Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ...

    • Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma 

      Lund, Johan; Gruber, Astrid; Lauri, Birgitta; Duru, Adil Doganay; Blimark, Cecilie; Swedin, Agneta; Hansson, Markus; Forsberg, Karin; Ahlberg, Lucia; Carlsson, Conny; Waage, Anders; Gimsing, Peter; Vangsted, Annette Juul; Frølund, Ulf; Holmberg, Erik; Gahrton, Gösta C.A.; Alici, Evren; Hardling, Mats; Mellqvist, Ulf-Henrik; Nahi, Hareth (Journal article; Peer reviewed, 2018)
      Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once ...

    • Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial 

      Schmitz, Alexander; Brøndum, Rasmus Froberg; Johnsen, Hans Erik; Mellqvist, Ulf-Henrik; Waage, Anders; Gimsing, Peter; Op Bruinink, Davine Hofste; van der Velden, Vincent; van der Holt, Bronno; Hansson, Markus; Andersen, Niels Frost; Frølund, Ulf Christian; Helleberg, Carsten; Schjesvold, Fredrik Hellem; Ahlberg, Lucia; Gulbrandsen, Nina; Andreasson, Bjorn; Lauri, Birgitta; Haukås, Einar; Bødker, Julie Støve; Roug, Anne Stidsholt; Bøgsted, Martin; Severinsen, Marianne T.; Gregersen, Henrik; Abildgaard, Niels; Sonneveld, Pieter; Dybkær, Karen (Peer reviewed; Journal article, 2022)
      Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer ...

    • Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials 

      Palumbo, Antonio; Waage, Anders; Hulin, Cyrille; Beksac, M; Zweegman, Sonja; Gay, Francesca; Gimsing, Peter; Leleu, X; Wijermans, P; Sucak, G; Pezzatti, S; Juliusson, Gunnar; Pegourie, B; Schaafsma, Marije; Galli, M; Turesson, Ingemar; Kolb, B; van der Holt, B; Baldi, I; Rolke, Jürgen; Ciccone, G; Wetterwald, M; Lokhorst, H; Boccadoro, Mario; Rodon, P; Sonneveld, Pieter (Journal article; Peer reviewed, 2013)
      Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a ...